Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort

Previous clinical studies had not shown expected results in advanced pancreatic cancer (APC) with single-agent checkpoint inhibitors. Until the present day, little is known about their performance in real-world settings. So, in this study, we investigate the ICIs’ efficacy and safety in Chinese APC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaoling, Zhu, Yahui, Zhang, Qianning, Qiu, Xin, Lu, Changchang, Tong, Fan, Wang, Qiaoli, Kong, Weiwei, Zhou, Haihui, Liu, Baorui, Zhou, Yujie, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746550/
https://www.ncbi.nlm.nih.gov/pubmed/36412232
http://dx.doi.org/10.1080/21645515.2022.2143154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746550/
https://www.ncbi.nlm.nih.gov/pubmed/36412232
http://dx.doi.org/10.1080/21645515.2022.2143154

Ejemplares similares